Bronchoscopy
Conditions
Brief summary
The aim of this study is to evaluate the effectiveness of a simple intervention through a classical Yankauer oral suction tube, a device known to have a proven safety profile in multiple healthcare settings, in decreasing the sedative and opioid medication doses needed to provide effective patient sedation during bronchoscopy, along with its effect on both patient's and bronchscopist's satisfaction throughout the procedure.
Interventions
DEVICEYankauer Suction Device
The Yankauer suction device is a hollow, curved and flexible tube that has a suction tip surrounded by a bulbous head to allow effective suctioning without damaging the surrounding tissue. It has been frequently used in multiple settings that range from minor dental procedures to large surgeries. It is also frequently used in the intensive care units to suction oropharyngeal secretions and prevent aspiration. Throughout this study, and regardless of the study group (control or intervention group), the Yankauer suction device is attached to a distinct suction port and placed, at the other end, inside the oral cavity of the patient.
PROCEDUREBronchoscopy
Flexible bronchoscopy done for the following indications: presence of a lung mass or collapse, persistent pulmonary infiltrates, pulmonary infection in the setting of immunosuppression, hemoptysis, or other rare causes like chronic cough. Flexible bronchoscopy (FB) is a medical procedure that has been used for more than five decades for the diagnostic evaluation and/or therapeutic intervention in a multitude of pulmonary and bronchial diseases
Sponsors
American University of Beirut Medical Center
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
DOUBLE (Subject, Caregiver)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* 18 years or above * inpatients or outpatients * scheduled to have a flexible bronchoscopy for one of multiple indications based on their physician's assessment, including the presence of a lung mass or collapse, persistent pulmonary infiltrates, pulmonary infection in the setting of immunosuppression, hemoptysis, or other rare causes like chronic cough. * patients provided a written informed consent.
Exclusion criteria
* patients with anatomic oro-pharyngeal abnormalities, * critically ill patients * uncooperative patients or inability to provide signed consent by the patient or their legal representative * coagulopathy or bleeding diathesis * severe obstructive airway disease * recent myocardial infarction * uncontrolled or poorly controlled asthma or chronic obstructive pulmonary disease (COPD) * pregnancy.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Mean doses of Midazolam and Fentanyl | From enrollment (pre-bronchoscopy) to the end of the bronchoscopic procedure (up to 30 minutes) | From the time of enrollment (pre-bronchoscopy) to the end of the bronchoscopic procedure |
Outcome results
None listed